Details for Patent: 11,497,718
Which drugs does patent 11,497,718 protect, and when does it expire?
Patent 11,497,718 protects VTAMA and is included in one NDA.
Summary for Patent: 11,497,718
| Title: | Use of tapinarof for the treatment of atopic dermatitis | ||||||||||||||||||||||||||||||||||||||
| Abstract: | Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3. | ||||||||||||||||||||||||||||||||||||||
| Inventor(s): | John E. KRAUS, James Lee | ||||||||||||||||||||||||||||||||||||||
| Assignee: | Dermavant Sciences GmbH | ||||||||||||||||||||||||||||||||||||||
| Application Number: | US16/682,485 | ||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | ||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | United States Patent 11,497,718: Tapinarof Atopic Dermatitis Claims, Patent Scope, and Generic Entry RiskU.S. Patent No. 11,497,718 protects a once-daily method of treating mild-to-moderate atopic dermatitis with an approximately 1.0% topical tapinarof composition. The independent claim combines the active ingredient, concentration, dosing frequency, disease severity, and clinical response. Dependent claims add the oil-in-water emulsion, specific excipients, patient population, treatment sites, clinical endpoints, durability of response, and low systemic exposure. The patent is method-of-use focused. It does not broadly claim tapinarof as a chemical compound or every tapinarof formulation. Its commercial relevance depends on whether the patented atopic dermatitis indication is approved, listed in the FDA Orange Book, and successfully enforced against a competing topical product. What does U.S. Patent 11,497,718 cover?The patent covers a treatment protocol with five central elements:
Claim 1 is the controlling independent claim. A potentially infringing product or treatment protocol would need to satisfy each limitation. A tapinarof product used twice daily, containing materially less or more than approximately 1.0%, or directed to a disease other than atopic dermatitis would present a different literal infringement analysis. The claim also requires a clinical outcome. The patient must experience an Investigator Global Assessment improvement of two grades or an improvement to IGA 0 or 1 after treatment. This outcome limitation narrows the claim but creates enforcement complexity because infringement may depend on patient results, clinical protocols, labeling, promotional materials, or post-launch evidence. How broad is the independent claim in Patent 11,497,718?Claim 1 is commercially meaningful but technically narrower than a general tapinarof treatment claim. It does not require:
The claim does require mild-to-moderate atopic dermatitis, approximately 1.0% tapinarof, once-daily topical administration, and the specified IGA result. The phrase “about 1.0%” will be important in an infringement dispute. Courts generally assess numerical ranges through claim construction, specification disclosure, prosecution history, and technical evidence. A product labeled as 1.0% tapinarof is directly within the apparent commercial target. Products labeled at 0.5% or 2.0% would require a separate analysis of the meaning of “about.” What formulations are protected by Patent 11,497,718?Claims 2 through 4 narrow the invention to an oil-in-water emulsion and then to particular oil- and water-phase ingredients. Oil-in-water emulsion claimClaim 2 requires the composition to be an oil-in-water emulsion. This limitation excludes other dosage forms unless they are legally characterized as oil-in-water emulsions. Creams, lotions, and emulsions can overlap commercially, but product nomenclature alone does not determine claim scope. Specific excipient claimClaim 3 identifies the oil phase as containing:
Claim 4 identifies the water phase as containing:
Claims 3 and 4 depend on claim 2. They therefore require the base method in claim 1, the oil-in-water emulsion, and the listed phase components. The claims do not necessarily require exclusive presence of those ingredients unless the patent’s claim construction or prosecution history gives “comprised of” a narrower meaning. “Comprising” ordinarily permits additional ingredients. These formulation claims can create a stronger product-specific enforcement position than claim 1 if a commercial formulation substantially matches the listed excipient system. They also provide design-around opportunities. A competitor could evaluate a water-in-oil vehicle, an anhydrous vehicle, a gel, a different emulsifier system, or a materially different preservative and antioxidant system. What patient populations and treatment sites are covered?Claims 5 through 8 define the target patient and disease presentation.
Claim 5 may align with an adult and adolescent label. Claim 7 is more restrictive because it defines the affected body surface area. Claim 8 requires an IGA score of at least 3, which generally corresponds to at least moderate baseline disease in commonly used atopic dermatitis trial designs. The combination of claims 7 and 8 is important in clinical-trial settings. A study or label limited to patients with a different BSA range or baseline severity may avoid those dependent claims while remaining potentially relevant to claim 1. What clinical outcomes are claimed?Claims 9 through 18 cover efficacy endpoints and durability. The claimed endpoints include:
Claim 10 requires a three-point improvement on the itch or pruritus numeric rating scale. Claim 11 requires EASI improvement of at least 50% or at least 75%. Claim 12 requires affected BSA to fall below 20%. Claims 15 and 17 cover improvement after approximately two, four, or eight weeks. Claims 16 and 18 extend the claimed benefit to approximately four weeks after treatment stops. These limitations are potentially valuable in a label-based infringement case if a competing label instructs use for the same disease and dosage regimen and describes the same response expectations. They are less straightforward where the claim requires actual patient outcomes rather than an instruction to achieve a result. Does Patent 11,497,718 cover low systemic exposure?Yes. Claim 19 requires that topical administration of approximately 1.0% tapinarof results in systemic tapinarof exposure below the limit of detection. This is a pharmacokinetic limitation. It may distinguish topical treatment from systemic administration and may support the safety rationale for the topical product. Enforcement would likely require validated bioanalytical testing, identification of the applicable detection limit, and analysis of whether the limitation refers to plasma, serum, or another biological matrix under the patent disclosure. The limitation can also create a design-around issue. A competing product with measurable systemic exposure could contest literal infringement of claim 19 while remaining exposed under claims 1 through 18. When does U.S. Patent 11,497,718 expire?The patent issued November 15, 2022. Its term is generally calculated from the earliest effective nonprovisional or international application filing date, subject to patent-term adjustment, terminal disclaimers, and any applicable patent-term extension. The tapinarof atopic dermatitis patent family is associated with a priority framework that places the ordinary 20-year term in approximately 2035 or 2036, depending on the relevant effective filing date and continuation history. The exact expiration date must be taken from the USPTO Patent Center record and the patent’s term-adjustment calculation. The issue date does not determine expiration. A later-issued patent can expire on the same date as an earlier family member if it claims priority to the same disclosure. What is the FDA regulatory status of tapinarof?The FDA approved tapinarof cream, 1%, marketed as Vtama, for the topical treatment of plaque psoriasis in adults on May 23, 2022. The approved product is an oil-in-water cream administered once daily. The FDA prescribing information identifies tapinarof as an aryl hydrocarbon receptor agonist and describes the product as a nonsteroidal topical treatment.[1] Patent 11,497,718 is directed to atopic dermatitis, not the original plaque psoriasis approval. That distinction affects Orange Book listing and generic litigation strategy. A method patent directed solely to an unapproved indication may not provide the same immediate listing value as a patent covering the approved product, its formulation, or the approved use. Tapinarof’s new chemical entity exclusivity began with the 2022 approval and generally provides five years of protection from certain ANDA submissions, subject to statutory exceptions. That period would ordinarily run to May 2027. Patent rights can extend beyond regulatory exclusivity. What is the Orange Book status of Patent 11,497,718?Orange Book relevance depends on the patent’s approved-use or product claims and FDA listing determinations. Patent 11,497,718 is a method-of-use patent directed to atopic dermatitis. If atopic dermatitis is not an approved Vtama indication, the patent’s listing position is materially different from a patent that claims the approved plaque psoriasis use or the marketed cream formulation. A listed method-of-use patent can support a Section viii statement when a generic applicant carves out the patented indication. A formulation or product patent may instead require a Paragraph IV certification if the applicant alleges that the patent is invalid, unenforceable, or not infringed. The Orange Book should be reviewed for:
Which companies are challenging tapinarof exclusivity?No widely reported Paragraph IV litigation involving U.S. Patent 11,497,718 was identified in the supplied record. A complete current challenger analysis requires live review of FDA Paragraph IV notices, district court dockets, ANDA litigation filings, and Orange Book updates. The likely challenger class is generic dermatology manufacturers with topical cream manufacturing capacity. Their principal options are:
Because the patent claims atopic dermatitis, a generic seeking only the plaque psoriasis indication may have a meaningful carve-out strategy if the FDA-approved label and use code permit it. How strong is the patent estate for tapinarof?Patent 11,497,718 is strongest against a product that matches the full commercial profile:
Its strength is lower against:
The estate should be assessed as a layered structure rather than through this patent alone:
What generic launch scenarios exist?Scenario 1: No atopic dermatitis carve-outA generic label includes atopic dermatitis and directs once-daily use of 1% tapinarof. This creates the highest risk under claim 1 and the related dependent claims. Scenario 2: Plaque psoriasis-only labelA generic omits atopic dermatitis. The applicant may avoid direct infringement of the principal method claim, depending on the approved label and actual marketing conduct. Formulation and compound patents remain relevant. Scenario 3: Formulation design-aroundA competitor uses a different vehicle or excipient architecture. This may avoid claims 2 through 4, but it does not automatically avoid claim 1. Scenario 4: Different strength or regimenA product uses a strength outside the legally applicable “about 1.0%” range or a different dosing schedule. This approach creates technical and clinical-development tradeoffs and does not eliminate risk under unrelated patent claims. Scenario 5: Post-expiration launchA generic waits until the relevant patent term ends. This removes infringement exposure from the expired patent but preserves any unexpired family, formulation, manufacturing, or regulatory barriers. What litigation and settlement issues matter?A Paragraph IV dispute would likely focus on:
Settlement agreements could establish a delayed launch date, authorized generic rights, supply arrangements, or restrictions on indication expansion. No settlement involving Patent 11,497,718 is identified in the supplied materials. Key Takeaways
FAQs About U.S. Patent 11,497,718Does Patent 11,497,718 protect Vtama for plaque psoriasis?No. The provided claims are directed to treating atopic dermatitis. Separate compound, formulation, and plaque psoriasis method patents may protect the marketed plaque psoriasis product. Can a generic launch tapinarof for plaque psoriasis before this patent expires?Potentially, if the generic omits atopic dermatitis and clears all other applicable patents and regulatory exclusivity barriers. The outcome depends on Orange Book listings, use codes, formulation claims, and the generic label. Is the exact Vtama cream formulation claimed?Claims 2 through 4 cover an oil-in-water emulsion and specified excipients. They may cover the commercial formulation if the product contains the claimed components in the claimed phase arrangement. Does the patent require eight weeks of treatment?No. Claims 15 and 17 identify improvement after approximately two, four, or eight weeks. Claim 1 does not expressly require an eight-week treatment period. Can a competing product avoid claim 19 by having detectable systemic exposure?Potentially. Detectable exposure could avoid the specific below-detection limitation in claim 19, but it would not by itself avoid the broader treatment method in claim 1 or the other dependent claims. References
More… ↓ |
Drugs Protected by US Patent 11,497,718
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Llc | VTAMA | tapinarof | CREAM;TOPICAL | 215272-001 | May 23, 2022 | RX | Yes | Yes | 11,497,718 | ⤷ Start Trial | TOPICAL TREATMENT OF ATOPIC DERMATITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
